Showing 5781-5790 of 9770 results for "".
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- ISHRS: Hair Restoration Surgery at All-Time Highhttps://practicaldermatology.com/news/ishrs-hair-restoration-surgery-at-all-time-high/2458029/Hair restoration is having a moment. The worldwide volume of surgical hair restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures performed worldwide in 2016, according to the latest’s statistics from the
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- SkinCeuticals Launches Two New Cosmeceutical Cleansershttps://practicaldermatology.com/news/skinceuticals-launches-two-new-cosmeceutical-cleansers/2458048/SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing Cleanser and Soothing Cleanser join SkinCeuticals&
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C